FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of formula (I), where R is hydrogen, and a pharmaceutical composition thereof for treating a skin disease associated with proteolytic activity of one or more KLK proteases.
EFFECT: disclosed are benzoxazinone compounds as double inhibitors of KLK5/7.
22 cl, 4 dwg, 3 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
KLK5-INHIBITING PEPTIDE | 2019 |
|
RU2826422C2 |
GAMMA-DIKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS | 2014 |
|
RU2680716C2 |
NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-d]PYRIMIDINE-2-(3H)-AMINE DERIVATIVES AND USE THEREOF IN THERAPY | 2007 |
|
RU2437889C2 |
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | 2007 |
|
RU2525392C2 |
INDAZOLIE WNT SIGNAL PATHWAY INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | 2017 |
|
RU2682245C1 |
INDASOLE INHIBITORS OF Wnt SIGNAL PATH AND THEIR THERAPEUTIC APPLICATIONS | 2013 |
|
RU2638932C2 |
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | 2007 |
|
RU2466729C2 |
PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2824528C2 |
NEW POTENTIAL ANTIFUNGAL AGENTS BASED ON THIAZOLIDINE-2,4-DIONE AND TRIAZOLE | 2023 |
|
RU2814730C1 |
Authors
Dates
2024-12-06—Published
2020-09-30—Filed